Catalyst Event
Biogen Inc (BIIB) · Other
From KEDI U.S. Tech100 90% Participation + Daily Options Premium Index (KUSTC100P)
5/21/2026, 12:00:00 AM
Biogen and partner Denali Therapeutics announced the discontinuation of development for their Parkinson's disease drug, BIIB122, after it failed to meet primary and secondary endpoints in a Phase 2b study.
Korean Translation
바이오젠과 파트너사 디날리 테라퓨틱스, 파킨슨병 치료제 후보물질 BIIB122가 임상 2b상에서 1차 및 2차 평가변수를 충족하지 못해 개발 중단을 발표함.
Related Recent Events
Datadog Inc (DDOG) · Earnings Release
Datadog Q2 2026 earnings release on August 6, 2026, scheduled. Market reaction is estimated to be significant (Medium) as earnings are primary price drivers for high-growth SaaS, scheduled
8/6/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Earnings Release
Rocket Lab's Q2 2026 earnings release on 2026-08-06 expected.
8/6/2026, 12:00:00 AM
AppLovin Corporation (APP) · Earnings Release
AppLovin's Q2 2026 earnings release, which typically has low immediate price impact upon date announcement, is scheduled.
8/5/2026, 12:00:00 AM
Amgen Inc (AMGN) · Earnings Release
Amgen's Q2 2026 earnings release is scheduled for 2026-07-30. Price impact is estimated at Medium (>=5%) as historical earnings reports typically drive significant volatility. Analysts forecast EPS of approximately $5.59 on revenues of $9.42 billion forecasted.
7/30/2026, 12:00:00 AM
Monolithic Power Systems Inc (MPWR) · Earnings Release
Monolithic Power Systems' Q2 2026 earnings release is scheduled for 2026-07-30, with company revenue of $890 million to $910 million forecasted; importance is Low as market reaction is pending.
7/30/2026, 12:00:00 AM
Meta Platforms Inc (META) · Earnings Release
Meta's Q2 2026 earnings release is expected. Low price impact is estimated for the date announcement, though the actual results will likely be a high-impact event.
7/29/2026, 12:00:00 AM